| Developing scalable machine learning-based approaches to classifying significant incidental findings in patients undergoing lung cancer screening |
Ilana Gareen |
Brown University |
NLST |
Jul 20, 2026 |
NLST-1517 |
| AEGIS — AI-Enabled Genomic and Integrated Stratification for Multi-Cancer Risk: Deep-Learning Development and Internal Validation in the PLCO Cohort |
Aneel Paulus |
West Eastern Health |
PLCO |
Jul 14, 2026 |
PLCO-2064 |
| Development of generalizable pathology foundation models for cancer prognosis using PLCO whole slide images |
Marvin Lerousseau |
Spotlight Medical, SAS |
PLCO |
Jul 14, 2026 |
PLCOI-2060 |
| External Validation of a Deep-Learning Atypical Mitosis Based Prognostic Model Using the PLCO Pathology Image Repository |
William Chen |
University of California, San Francisco |
PLCO |
Jul 14, 2026 |
PLCOI-2059 |
| NeuroAI-PLCO Images: Longitudinal Risk Stratification Using PLCO Imaging and Structured Data |
Richard Tran |
Trove-AI |
PLCO |
Jul 14, 2026 |
PLCOI-2056 |
| Developing Quantitative AI-histologic Signatures Associated with Prognosis and Treatment Benefit Across Cancer Types in the PLCO Trial |
Haochen Zhang |
Valar Labs |
PLCO |
Jul 14, 2026 |
PLCOI-2054 |
| NeuroAI-Lung: Longitudinal Risk Stratification Using NLST Low-Dose CT Data |
Richard Tran |
Trove-AI |
NLST |
Jul 14, 2026 |
NLST-1519 |
| PLCO Germline Materials for Integrated Whole-Genome Discovery of Lung Cancer Susceptibility with the Sherlock-Lung Study |
Maria Teresa Landi |
National Cancer Institute, National Institutes of Health |
PLCO |
Jul 8, 2026 |
2026-0117 |
| Repurposing: Efficient use of excess PLCO biospecimens to investigate DNA methylation patterns and cardiovascular disease mortality risk |
Jason Wong |
National Heart Lung and Blood Institute |
PLCO |
Jun 25, 2026 |
2026-8083 |
| ABO Blood Type and Secretor Status as Determinants of Oral Microbiome Composition and Cancer Risk: Evidence from the PLCO Cohort |
Emily Vogtmann |
National Cancer Institute |
PLCO |
Jun 18, 2026 |
PLCO-2058 |
| Longitudinal study of socioeconomic factors, stress-related biomarkers, and aggressive prostate cancer |
Kathryn Barry |
University of Maryland, Baltimore |
PLCO |
Jun 17, 2026 |
2026-0158 |
| Multi-population study of serum protein biomarkers and prostate cancer risk |
Sonja Berndt |
National Cancer Institute |
PLCO |
Jun 17, 2026 |
2026-0154 |
| Leveraging antibody responses against transposable elements as a novel immune therapy for ovarian cancer |
Rebecca Lynch |
The George Washington University School of Medicine and Health Sciences |
PLCO |
Jun 17, 2026 |
2026-0096 |
| Exosome-based microRNA Biomarkers for Non-invasive and Early Detection of Colorectal Cancer and Advanced Adenomas |
Ajay Goel |
City of Hope |
PLCO |
Jun 16, 2026 |
2025-0016 |
| Efficient Design and Analysis of Two-Phase Biomarker Studies |
Li Cheung |
National Cancer Institute |
PLCO |
Jun 8, 2026 |
PLCO-2053 |
| PLCO Digital Pathology Whole-Slide Images for Prostate, Lung, and Ovarian Cancer AI Modeling and Validation |
Yuming Jiang |
Wake Forest University Health Sciences |
PLCO |
Jun 8, 2026 |
PLCOI-2052 |
| Impact of deep learning lung cancer risk models on clinical decisions with blood-based diagnostics |
Michael Kammer |
Biodesix, inc |
NLST |
Jun 8, 2026 |
NLST-1515 |
| Designing a Targeted Lung Cancer (LC) Screening Trial in the U.S. Screening-Ineligible Population Using Synthetic Cohorts and Natural History Modelling |
Thomas Trikalinos |
Brown University |
PLCO |
Jun 1, 2026 |
PLCO-2047 |
| Scalable and Reproducible Deep Learning Strategies for Lung Cancer Screening Imaging |
Stefano Diciotti |
Alma Mater Studiorum - Department DEI |
NLST |
Jun 1, 2026 |
NLST-1514 |
| Deep Learning to Improve Screening of Interstitial Lung Diseases (NLST-1505 continued) |
Charles Hatt |
IMBIO, a 4D Medical Company |
NLST |
Jun 1, 2026 |
NLST-1506 |
